학술논문

No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)
Document Type
Article
Source
In: Diabetes, Obesity and Metabolism. (Diabetes, Obesity and Metabolism, December 2023, 25(12):3621-3631)
Subject
Language
English
ISSN
14631326
14628902